SHARE
COPY LINK

HEALTH

Switzerland could vote again on legalising cannabis

Swiss citizens could vote on whether to legalise cannabis after a new citizens' initiative proposed the legalisation, possession, cultivation, and sale of the drug in Switzerland.

Switzerland could vote again on legalising cannabis
Switzerland could vote again on whether to legalise cannabis.(Photo by Fabrice COFFRINI / AFP)

The new initiative was announced by the Federal Chancellery.

The initiative entitled “Legalising cannabis: an opportunity for the economy, health and equality” also calls for revenues from the taxation of cannabis products to be allocated to drug prevention as well as a campaign by the government to highlight the health risks of cannabis.

The organisers have 18 months – until October 2025 – to collect the 100,000 signatures required for a popular initiative to brought to the ballot box on a national level.

Cannabis has been illegal in Switzerland since 1951 and its use has been punishable by law since 1975. But national statistics say there are around 300,000 cannabis users in the country.

The new initiative states: “Legislation regarding the cultivation, possession and personal use of cannabis is the responsibility of the Confederation. Citizens who have reached the age of 18 can cultivate and possess cannabis.”

Cultivation and sale for commercial purposes would be permitted, the initiative states. Farms and points of sale would be subject to licensing and strict quality and safety standards. Individuals would be limited to growing 50 cannabis plants at home.

READ ALSO: What are Switzerland’s current rules on cannabis?

In a previous referendum held on this issue in 2008, 63 percent of voters rejected the legalisation. Since then, however, the tide may have turned, according to a government survey published in 2021.

In the meantime, several Swiss cities — Basel, Zurich, Geneva, Bern, Lausanne, and Lucerne — have launched pilot projects to see what health and social effects the regulated sale of cannabis has on its users, and society in general.

Member comments

Log in here to leave a comment.
Become a Member to leave a comment.
For members

HEALTH

Which medications in Switzerland are set to become more expensive?

The cost of medications in Switzerland is already quite a bit higher than elsewhere in Europe. And now certain drugs will become even pricier.

Which medications in Switzerland are set to become more expensive?

Swiss consumers pay significantly more for their medicines than those in neighbouring European countries. 

This is what emerges from various data published over the years.

“In Switzerland, we pay far too much for medicines compared to abroad,” Matthias Müller, a spokesperson for SantéSuisse, an umbrella group for Swiss health insurance providers, told Swiss media in 2023. 

Even the price of many generic medicines is twice as high in Switzerland as in nine EU countries.

For instance, generics are on average 48 percent cheaper in Belgium, Denmark, Germany, Finland, France, Great Britain, the Netherlands, Austria and Sweden than in Switzerland, according to a price comparison.

And prices for a number of commonly-used drugs will rise even further in the near future.

Why is that?

The Federal Office of Public Health (FOPH) is adapting a new model for calculating the distribution margin. 

A distribution margin is the difference between the distributor’s cost of acquiring goods and the price at which those goods are sold.

From July 1st, 2024, inexpensive medicines whose factory price is less than, or equal to, 15 francs will become more expensive.

This change will affect more than half of medications currently being sold in Switzerland.

As a result of this move, “additional costs of several hundred million will be passed on to patients,” according to Intergenrika, which represents generic drug manufacturers in Switzerland. 

In a nutshell, consumers will pay slightly lower prices for medicines that were previously more expensive, but will also end up paying more  for those that are currently cheaper – like generics.

Which meds will become more expensive?

Pain medications are among those set to become pricier.

One of them is ibuprofen, a popular anti-inflammatory.

While a box of 20 400-mg tablets today costs 5.92 francs, its price will practically double to 11 francs from July 1st.

Though its manufacturing cost will remain the same as today – 1.58 francs – the distribution margin will increase from 4.19 to 9.09 francs.

The same goes for another often-used pain medication, Ponstan.

Ten 500-mg tablets will cost 11.21 francs instead of 6.19 currently.

The manufacturer will continue to charge 1.82 francs for the drug, but the distribution margin will increase from 4.22 to 9.11 francs.

And even generic drugs, which are cheaper – and often by much – will get pricier, at consumers’ expense.

Will some drugs be cheaper?

Yes, some will become slightly less expensive.

One example is the anticoagulant Rivaroxaban whose price will drop from 281 to 267 francs.

READ ALSO: Why you will pay more for certain drugs in Switzerland 2024?

SHOW COMMENTS